

## Drugs Used in Inflammatory Bowel Diseases

- IBDs are **auto-immune** disorders, major types are **Crohn's disease** and **Ulcerative colitis**.
- **Symptoms**: vomiting, abdominal pain, diarrhea, rectal bleeding and weight loss.
- **Complications**: anemia, obstruction in CD, colon cancer in UC and mega colon.
- **Crohn's disease**: affects any part, skip lesions, deep, and may cause fistulas, strictures, etc.
- **Ulcerative colitis**: affects the colon only, continuous inflammation, shallow, may cause colon cancer and toxic mega colon.
- Treatment is only for maintaining remission and preventing relapse, it is **not curative**.
- **Tx**:
  - 1- 5-amino salicylic acid compounds (5-ASA).
  - 2- Glucocorticoids.
  - 3- Immunomodulators.
  - 4- Biological therapy
  - 5- Surgery if severe.

### 1- 5-ASA

- Topical.
- Formulations are used to **overcome 5-ASA early absorption** and thus delivered to the terminal ileum and colon, by being:
  - a- Azo compounds.**
  - b- Mesalamine compounds.**
- 5- ASA inhibits T-cell activation and proliferation and PG/LT/cytokine synthesis.

	Drug	Mechanism	Side effects	Notes
<b>A- Azo compounds</b>  5-ASA connected by an azo bond (N=N) to:  + <i>Sulphapyridine</i> → <i>Sulfasalazine</i> .  + 5-ASA → <i>Olsalazine</i>  + <i>Inert carrier</i> → <i>Balsalazide</i>	<b>Sulfasalazine</b>	- Oral pro-drug.  In the terminal ileum and colon, flora releases azoreductase forming:  <b>a- 5-ASA:</b> (not absorbed, active moiety)  <b>b- Sulphapyridine:</b> (absorbed, side effects)	- Can be Dose related or Idiosyncratic (rare).  <b>Idiosyncratic:</b> <b>1- Blood disorders:</b> Agranulocytosis, anemia, leukopenia, thrombocytopenia. <b>2- Skin reactions:</b> Lupus like syndrome, Stevens-Johnson syndrome, alopecia.  <b>Contraindications:</b> - <b>5-ASA</b> → Salicylate hypersensitivity + interstitial nephritis. - <b>Sulfapyridine</b> → G6PD deficiency + slow acetylator status.	<b>1-</b> Induction and maintenance of remission. <b>2-</b> Used in <b>UC</b> more (First line of treatment).  - Used for rheumatoid arthritis.  - Rectal formulations are used in active distal UC ulcerative proctitis and proctosigmoiditis.  <b>More side effects:</b> Folic acid deficiency + male infertility ( <b>oligospermia</b> )

	Drug	Mechanism	Notes
<b>B- Mesalamine compounds</b>  <i>Coated</i>	<i>Oral:</i> <b>Asacol</b> <b>Pentasa</b>  <i>Rectal:</i> <b>Rowasa</b> <b>Canasa</b>	- Oral formulations: <b>1- Asacol</b> (controlled release): coated in pH-sensitive resin that dissolved at pH 7. <b>2- Pentasa</b> (delayed release): time-released 5-ASA throughout the small intestine.	<b>1-</b> Induction and maintenance of remission. <b>2-</b> Used for <b>UC</b> more.  <u>Advantages:</u> Well tolerated and sulfa free, thus less side effects and useful in patient sensitive or allergic to sulfa drugs.

## 2- Glucocorticoids

- **Mechanism of action:** Inhibits phospholipase A2 // Inhibits gene transcription of NO synthase, cyclooxygenase-2 (COX-2). Inhibit production of inflammatory cytokines // Decrease antigen-antibody reaction.
- **Uses of glucocorticoids:**
  - 1- Induction of remission only; **not** used for maintaining remission.
  - 2- Used for **both** UC and CD.
  - 3- Oral glucocorticoids is commonly used in active disease conditions.
  - 4- Rectal glucocorticoids are preferred in IBD involving rectum or sigmoid colon.

Drug	Mechanism	Notes
<b>Prednisone, prednisolone.</b>	- Orally. - Has higher rate of absorption.	- More adverse effects compared to rectal administration.
<b>Budesonide</b>	- Orally, controlled release tablets in ileum and colon. - Low oral bioavailability (10%), thus less side effects.	- Subject to <b>first pass metabolism</b> .

## 3- Immunomodulators

- Used in IBD active severe conditions and in **steroid resistant patients**.

Drug	Action	Side Effects
<b>Purine analogs</b>  <i>(azathioprine and 6-mercaptopurine)</i>	- It <b>inhibits purine synthesis</b> . <b>1-</b> Induction and maintenance of remission. <b>2-</b> Used in <b>both</b> UC and CD.  - <u>Important:</u> Azathioprine is a pro-drug of 6-mercaptopurine, a substance that is metabolized into a cytotoxic 6-thioguanine, while an enzyme (TPMT) inactivates 6-mercaptopurine through methylation, thus deficiency in TPMT causes a life-threatening bone marrow suppression due to the accumulation of an active cytotoxic 6-thioguanine.	- <b>Bone marrow suppression:</b> leucopenia, thrombocytopenia, and myelotoxicity, determined by TPMT activity. - Gastrointestinal toxicity. - Hepatic dysfunction. - Pancreatitis. - Complete blood count and liver function tests are required in all patients
<b>Methotrexate</b>  <i>Orally, SC., IM</i>	- <b>Folic acid antagonist.</b> - Inhibits dihydrofolate reductase required for folic acid activation. <b>1-</b> Used to induce and maintain remission. <b>2-</b> For <b>CD</b> only.  - Used for Rheumatoid arthritis and Cancer.	- Bone marrow depression. - Megaloblastic anemia.

## 4- Biological Therapy

- Monoclonal antibodies (**TNF- $\alpha$  inhibitors**).

Drug	Mechanism	Side Effects	Notes
<b>Infliximab</b> IV	<ul style="list-style-type: none"> <li>- Inhibits TNF-<math>\alpha</math>.</li> <li>- Long half-life (8-10 days)</li> <li>- 2 weeks to give clinical response.</li> </ul>	<ul style="list-style-type: none"> <li>- <b>Allergic reactions</b> 10% of patients.</li> <li>- Delayed infusion reaction (serum sickness-like reaction).</li> <li>→ <i>Pretreatment with diphenhydramine, acetaminophen, corticosteroids is recommended.</i></li> <li>- <b>Reactivation</b> of Tuberculosis and HBV.</li> <li>- Patient may become resistant.</li> <li>- Severe hepatic failure and rare risk of lymphoma.</li> </ul>	<ul style="list-style-type: none"> <li>- A <b>chimeric mouse-human</b> monoclonal antibody (25% murine – 75% human).</li> <li><b>1-</b> Induction and maintenance of remission.</li> <li><b>2-</b> Used for <b>both</b> UC and CD.</li> <li><u>Used for:</u></li> <li>- Patients not responding to immunomodulators or glucocorticoids.</li> <li>- Treatment of rheumatoid arthritis and Psoriasis.</li> </ul>
<b>Adalimumab</b> Subq (advantage)	<ul style="list-style-type: none"> <li>- Inhibits TNF<math>\alpha</math>.</li> </ul>	-	<ul style="list-style-type: none"> <li>- <b>Fully humanized</b> IgG antibody to TNF-<math>\alpha</math></li> <li><b>1-</b> Induction and maintenance of remission.</li> <li><b>2-</b> Used for <b>both</b> UC and CD.</li> <li>Used for: Rheumatoid arthritis and Psoriasis.</li> </ul>
<b>Certolizumab</b> Subq (The Dr. didn't emphasize on it)	-	<ul style="list-style-type: none"> <li>- Immunogenicity appears to be <b>less</b> of a problem than with infliximab.</li> </ul>	<ul style="list-style-type: none"> <li>- Polyethylene glycol Fab fragment of <b>humanized</b> anti-TNF-<math>\alpha</math>.</li> </ul>

### The doctor emphasized on:

- Knowing: **1- Induction/Maintenance?** **2- For CD/UC?** for each drug, showed in the table with the respective number.
- **TPMT activity** and its influence on purines analogs' side effect.
- Budesonide is subject to the first bypass effect.
- Infliximab is chimeric (mouse + human antibodies), while Adalimumab and Certolizumab are fully humanized.
- **Asacol** → pH-dependent, mainly on colon. **Pentasa** → Time-dependent, mainly on terminal ileum.
- Understand the side effect of steroids, as shown in the figure to the right:

